Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly - PubMed (original) (raw)
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly
Dirk Spitzer et al. J Immunol. 2007.
Abstract
Complement promotes the rapid recognition and elimination of pathogens, infected cells, and immune complexes. The biochemical basis for its target specificity is incompletely understood. In this report, we demonstrate that properdin can directly bind to microbial targets and provide a platform for the in situ assembly and function of the alternative pathway C3 convertases. This mechanism differs from the standard model wherein nascent C3b generated in the fluid phase attaches nonspecifically to its targets. Properdin-directed complement activation occurred on yeast cell walls (zymosan) and Neisseria gonorrhoeae. Properdin did not bind wild-type Escherichia coli, but it readily bound E. coli LPS mutants, and the properdin-binding capacity of each strain correlated with its respective serum-dependent AP activation rate. Moreover, properdin:single-chain Ab constructs were used to direct serum-dependent complement activation to novel targets. We conclude properdin participates in two distinct complement activation pathways: one that occurs by the standard model and one that proceeds by the properdin-directed model. The properdin-directed model is consistent with a proposal made by Pillemer and his colleagues >50 years ago.
Similar articles
- An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.
Agarwal S, Ferreira VP, Cortes C, Pangburn MK, Rice PA, Ram S. Agarwal S, et al. J Immunol. 2010 Jul 1;185(1):507-16. doi: 10.4049/jimmunol.0903598. Epub 2010 Jun 7. J Immunol. 2010. PMID: 20530262 Free PMC article. - Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
Vuagnat BB, Mach J, Le Doussal JM. Vuagnat BB, et al. Mol Immunol. 2000 Jun;37(8):467-78. doi: 10.1016/s0161-5890(00)00069-9. Mol Immunol. 2000. PMID: 11090881 - Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.
Kimura Y, Miwa T, Zhou L, Song WC. Kimura Y, et al. Blood. 2008 Jan 15;111(2):732-40. doi: 10.1182/blood-2007-05-089821. Epub 2007 Oct 4. Blood. 2008. PMID: 17916747 Free PMC article. - Properdin and complement activation: a fresh perspective.
Hourcade DE. Hourcade DE. Curr Drug Targets. 2008 Feb;9(2):158-64. doi: 10.2174/138945008783502458. Curr Drug Targets. 2008. PMID: 18288967 Review. - Properdin: New roles in pattern recognition and target clearance.
Kemper C, Hourcade DE. Kemper C, et al. Mol Immunol. 2008 Oct;45(16):4048-56. doi: 10.1016/j.molimm.2008.06.034. Epub 2008 Aug 8. Mol Immunol. 2008. PMID: 18692243 Free PMC article. Review.
Cited by
- The role of properdin in zymosan- and Escherichia coli-induced complement activation.
Harboe M, Garred P, Lindstad JK, Pharo A, Müller F, Stahl GL, Lambris JD, Mollnes TE. Harboe M, et al. J Immunol. 2012 Sep 1;189(5):2606-13. doi: 10.4049/jimmunol.1200269. Epub 2012 Jul 30. J Immunol. 2012. PMID: 22851705 Free PMC article. - New insights into the pathogenesis of IgA nephropathy.
Floege J, Moura IC, Daha MR. Floege J, et al. Semin Immunopathol. 2014 Jul;36(4):431-42. doi: 10.1007/s00281-013-0411-7. Epub 2014 Jan 18. Semin Immunopathol. 2014. PMID: 24442210 Review. - Fluid phase recognition molecules in neutrophil-dependent immune responses.
Jaillon S, Ponzetta A, Magrini E, Barajon I, Barbagallo M, Garlanda C, Mantovani A. Jaillon S, et al. Semin Immunol. 2016 Apr;28(2):109-18. doi: 10.1016/j.smim.2016.03.005. Epub 2016 Mar 25. Semin Immunol. 2016. PMID: 27021644 Free PMC article. Review. - Complement-targeted therapeutics in periodontitis.
Hajishengallis G, Lambris JD. Hajishengallis G, et al. Adv Exp Med Biol. 2013;735:197-206. doi: 10.1007/978-1-4614-4118-2_13. Adv Exp Med Biol. 2013. PMID: 23402028 Free PMC article. Review. - Complement in Tumourigenesis and the Response to Cancer Therapy.
O'Brien RM, Cannon A, Reynolds JV, Lysaght J, Lynam-Lennon N. O'Brien RM, et al. Cancers (Basel). 2021 Mar 10;13(6):1209. doi: 10.3390/cancers13061209. Cancers (Basel). 2021. PMID: 33802004 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous